Divi’s Labs Announces INR 700 Cr Expansion Plan
The Indian drugmaker will manufacture and supply advanced intermediates under the agreed commercial terms.
Hyderabad-based Divi's Laboratories has entered into a supply agreement with a global pharmaceutical company.
The information has been revealed via a filing with the stock exchange.
The Indian drugmaker will manufacture and supply advanced intermediates under the agreed commercial terms.
While the identity of the international partner remains undisclosed, the company expects this long-term agreement to generate significant revenue in the coming years.
In line with this development, Divi’s Labs plans to invest between INR 650 Cr and INR 700 Cr to expand capacity at its manufacturing facilities.
The investment will be funded entirely through internal accruals.
The company emphasized that the deal ensures a reliable supply for its global partner and supports Divi’s ambition to deepen its presence in the custom synthesis segment of the pharmaceutical market.
Divi's Laboratories specializes in manufacturing active pharmaceutical ingredients (APIs) and intermediates and offers global custom synthesis services.
